up daily, and when possible, an outpatient visit on the 10th study day was conducted. Antibiotic susceptibility testing was completed by using the disk diffusion method. End points studied included the number of days until resolution of dysentery, fever, and therapeutic support with intravenous or oral fluids and electrolytes.
One hundred thirty adults volunteered for inclusion into the study and were randomized to receive treatment. At study completion, 113 (87%) were evaluable; the most common reason for study withdrawal was leaving the hospital before completion of the study drug regimen. Sixty-eight men and 45 women finished the study, of whom 57 received a single dose of azithromycin and 56 received 3 days of ciprofloxacin (table 1) . Dysentery in all study patients cleared (median time of clearance, 2 days) during observation. There were no significant differences between the drug assignment groups in terms of age, sex, the number of days until resolution of dysentery, fever, or therapeutic support with fluids on either an intent-to-treat or study completion basis. S dysenteriae type 1 isolates were resistant to all commonly prescribed drugs: 99% were resistant to tetracycline; 98%, to ampicillin; 100%, to trimethoprim-sulfamethoxazole; 69%, to amoxicillin/clavulanic acid; and 98%, to erythromycin. The same isolates were susceptible to nalidixic acid (83%), norfloxacin (100%), and gentamicin (100%). All 23 S. dysenteriae type 1 isolates tested were found to be susceptible to azithromycin (MIC 4 g/mL). Cultures of follow-up stool specimens did not yield any Shigella species, and no serious adverse effects of medication were noted.
Azithromycin in a 1-g oral dose is a potentially useful regimen when faced with a public health emergency caused by a severe dysentery epidemic; this treatment may be particularly helpful when dealing with pediatric patients, as a relative contraindication to the use of fluoroquinolones for children does exist. In areas where older antimicrobials are no longer reliably effective, a directly observed single-dose therapy might allow for cost containment by reducing the number of treatment failures due to noncompliance. A shorter duration of therapy with a quinolone has been studied [6] . Given this brief antibiotic exposure, however, the potential for the development of resistance cannot be ignored. In contrast, therapy with a 1-g dose of azithromycin would be expected to provide intracellular levels of drug that exceed the MIC for Shigella for as long as 14 days [7] . The data presented here expand the experience reported from Bangladesh, where 5 days of azithromycin (total dose, 1.5 g) was as effective against shigellosis as 5 days of ciprofloxacin [5] . Although the use of azithromycin in the treatment of other diarrheal diseases is still under evaluation, a single 1-g dose of azithromycin is effective and welltolerated treatment of epidemic dysentery. 
